SCHEMBL5645852

SCHEMBL5645852

CCC(C=O)c1ccc(S(=O)(=O)NC)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
GAA P10253 1/20 0.47
CA2 P00918 4/20 0.46
CA12 O43570 3/20 0.46
CA9 Q16790 3/20 0.46
CA1 P00915 3/20 0.46
CA3 P07451 2/20 0.46
CA4 P22748 2/20 0.46
CA6 P23280 2/20 0.46
CA5A P35218 2/20 0.46
CA7 P43166 2/20 0.46
CA13 Q8N1Q1 2/20 0.46
CA14 Q9ULX7 2/20 0.46
CA5B Q9Y2D0 2/20 0.46
LMNA P02545 2/20 0.44
HTT P42858 1/20 0.44
ALDH1A1 P00352 4/20 0.43
NR3C2 P08235 1/20 0.39
TAS2R14 Q9NYV8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647588 0.81 ENPP2 (0.41) LMNA
SCHEMBL15835045 0.79 SMN1; SMN2 (0.53) SMN1; SMN2GAACA2CA12CA9
SCHEMBL5649208 0.77 SMN1; SMN2 (0.52) SMN1; SMN2GAACA2CA12CA9
SCHEMBL8693004 0.73 LMNA (0.49) SMN1; SMN2CA2CA12CA9CA1
SCHEMBL7629070 0.73 SMN1; SMN2 (0.80) SMN1; SMN2GAACA2CA12CA9
SCHEMBL29511565 0.73 SMN1; SMN2 (0.44) SMN1; SMN2GAACA2CA12CA9
SCHEMBL7623081 0.72 TYR (0.50) SMN1; SMN2LMNAHTTALDH1A1L3MBTL1
SCHEMBL1545593 0.72 CA12 (0.63) SMN1; SMN2GAACA2CA12CA9
SCHEMBL13631877 0.72 HDAC8 (0.32) LMNADRD1
SCHEMBL23580752 0.71 ADRB2 (0.40) LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070049620-A1 Cyclic tertiary amine compound SANKYO COMPANY, LIMITED (JP) 2007-03-01 US disclosed
CN-1863793-A Cyclic tertiary amine compound SANKYO CO (JP) 2006-11-15 CN disclosed
EP-1632488-A1 CYCLIC TERTIARY AMINE COMPOUND Sankyo Company, Limited (JP) 2006-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049620-A1 Cyclic tertiary amine compound MYD88, IL5, BRD4 SMN1; SMN2 4635/4885GAA 4809/4885CA2 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.